Multidrug resistance in relapsed acute myeloid leukemia: Evidence of biological heterogeneity

Cancer

Volumn 119, Issue 16, 2013, Pages 3076-3083

  Patel, Chirayu ^a,b   Stenke, Leif ^c   Varma, Sudhir ^d   Lindberg, Marita Lagergren ^c   Björkholm, Magnus ^c   Sjöberg, Jan ^c   Viktorsson, Kristina ^c   Lewensohn, Rolf ^c   Landgren, Ola ^a   Gottesman, Michael M ^a   Gillet, Jean Pierre ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c KAROLINSKA INSTITUTE   (Sweden)

^d NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

acquired drug resistance; acute myeloid leukemia; leukemia cell lines; multidrug resistance; therapy related drug resistance

Indexed keywords

CYTARABINE; DAUNORUBICIN; ETOPOSIDE; IDARUBICIN; MITOXANTRONE; RNA; TIOGUANINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CYTOGENETICS; DRUG RESPONSE; FEMALE; GENE EXPRESSION PROFILING; HUMAN; IN VITRO STUDY; KARYOTYPE; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; MALE; MULTIDRUG RESISTANCE; OVERALL SURVIVAL; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 84881478906     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28098     Document Type: Article

References (24)

1. Shipley JL, Butera JN,. Acute myelogenous leukemia. Exp Hematol. 2009; 37: 649-658.
2. Walter MJ, Shen D, Ding L, et al. Clonal architecture of secondary acute myeloid leukemia. N Engl J Med. 2012; 366: 1090-1098.
3. Calcagno AM, Kim IW, Wu CP, Shukla S, Ambudkar SV,. ABC drug transporters as molecular targets for the prevention of multidrug resistance and drug-drug interactions. Curr Drug Deliv. 2007; 4: 324-333.
4. Leith C,. Multidrug resistance in leukemia. Curr Opin Hematol. 1998; 5: 287-291.
5. Marie JP, Legrand O,. MDR1/P-GP expression as a prognostic factor in acute leukemias. Adv Exp Med Biol. 1999; 457: 1-9.
6. Wuchter C, Leonid K, Ruppert V, et al. Clinical significance of P-glycoprotein expression and function for response to induction chemotherapy, relapse rate and overall survival in acute leukemia. Haematologica. 2000; 85: 711-721.
7. Gruber A, Bjorkholm M, Brinch L, et al. A phase I/II study of the MDR modulator Valspodar (PSC 833) combined with daunorubicin and cytarabine in patients with relapsed and primary refractory acute myeloid leukemia. Leuk Res. 2003; 27: 323-328.
8. Libby E, Hromas R,. Dismounting the MDR horse. Blood. 2010; 116: 4037-4038.
9. Shaffer B, Gillet J-P, Patel C, Baer M, Bates S, Gottesman MM,. Drug resistance: still a daunting challenge to the successful treatment of AML. Drug Resist Updat. 2012; 15: 62-69.
10. Gillet JP, Gottesman MM,. Mechanisms of multidrug resistance in cancer. Methods Mol Biol. 2010; 596: 47-76.
11. van der Kolk DM, de Vries EG, Noordhoek L, et al. Activity and expression of the multidrug resistance proteins P-glycoprotein, MRP1, MRP2, MRP3 and MRP5 in de novo and relapsed acute myeloid leukemia. Leukemia. 2001; 15: 1544-1553.
12. Gillet JP, Gottesman MM,. Advances in the molecular detection of ABC transporters involved in multidrug resistance in cancer. Curr Pharm Biotechnol. 2011; 12: 686-692.
13. Gillet JP, Wang J, Calcagno AM, et al. Clinical relevance of multidrug resistance gene expression in ovarian serous carcinoma effusions. Mol Pharm. 2011; 8: 2080-2088.
14. Derolf AR,. Predictors of Prognosis in Acute Myeloid Leukemia: a Clinical and Epidemiological Study [thesis]. Stockholm, Sweden: Karolinska University Hospital Solna and Institutet; 2010: 56.
15. Calcagno AM, Salcido CD, Gillet JP, et al. Prolonged drug selection of breast cancer cells and enrichment of cancer stem cell characteristics. J Natl Cancer Inst. 2010; 102: 1637-1652.
16. Simon R, Lam A, Li MC, Ngan M, Menenzes S, Zhao Y,. Analysis of gene expression data using BRB-ArrayTools. Cancer Inform. 2007; 3: 11-17.
17. Pfaffl MW,. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 2001; 29: e45.
18. Bennett JM, Catovsky D, Daniel MT, et al. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann Intern Med. 1985; 103: 620-625.
19. Wang ES, Sait SN, Gold D, et al. Genomic, immunophenotypic, and NPM1/FLT3 mutational studies on 17 patients with normal karyotype acute myeloid leukemia (AML) followed by aberrant karyotype AML at relapse. Cancer Genet Cytogenet. 2010; 202: 101-107.
20. Rottenberg S, Vollebergh MA, de Hoon B, et al. Impact of intertumoral heterogeneity on predicting chemotherapy response of BRCA1-deficient mammary tumors. Cancer Res. 2012; 72: 2350-2361.
21. Golub TR, Slonim DK, Tamayo P, et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science. 1999; 286: 531-537.
22. Haferlach T, Kohlmann A, Wieczorek L, et al. Clinical utility of microarray-based gene expression profiling in the diagnosis and subclassification of leukemia: report from the International Microarray Innovations in Leukemia Study Group. J Clin Oncol. 2010; 28: 2529-2537.
23. Theilgaard-Monch K, Boultwood J, Ferrari S, et al. Gene expression profiling in MDS and AML: potential and future avenues. Leukemia. 2011; 25: 909-920.
24. Marcucci G, Haferlach T, Döhner H,. Molecular genetics of adult acute myeloid leukemia: prognostic and therapeutic implications. J Clin Oncol. 2011; 29: 475-486.